Sign in
Active, not recruitingNo phase

China S3 PMS: SAPIEN 3 China Post Market Registry Study

Key facts

Who runs it
Edwards Lifesciences
Where
China14 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
250 people enrolled
Started
24 Jan 2022
Expected to end
Dec 2035
Type of study
Observational
Treatments tested
  • SAPIEN 3 Transcatheter Heart Valve
Record updated
12 August 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Patient with symptomatic, severe, calcified aortic stenosis who is appropriate for the treatment with transcatheter aortic valve replacement as determined by a heart team and will undergo TAVI with the Edwards SAPIEN 3 System as part of standard-of-care treatment
  • All surgical risks as determined by the site Heart Team
  • The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent

Who cannot take part

  • Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  • Participating in a drug or device study that has not reached its primary endpoint
  • Medical, social, or psychological conditions that preclude appropriate consent and follow-up, including subjects under guardianship
  • Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis
  • Considered to be part of a vulnerable population
  • Pre-existing mechanical or bioprosthetic aortic valve
  • Cannot tolerate an anticoagulation/antiplatelet regimen
  • Tortuous or calcified vessels that would prevent safe entry of the dilators and sheath

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objective of this study is to evaluate the long term safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve system in real world setting.

The group in the trial

  • Transcatheter Aortic Valve Implantation (TAVI)

    Treatment: SAPIEN 3 Transcatheter Heart Valve

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SAPIEN 3 China Post Market Registry Study
Record updated
12 August 2026